ImmuCell Corporation (ICCC)

Currency in USD
6.110
0.000(0.00%)
Real-time Data·
ICCC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.1106.110
52 wk Range
4.2807.600
Key Statistics
Prev. Close
6.11
Open
6.11
Day's Range
6.11-6.11
52 wk Range
4.28-7.6
Volume
-
Average Volume (3m)
25.41K
1-Year Change
21.7131%
Book Value / Share
3.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICCC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

ImmuCell Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Employees
81

ImmuCell Corporation Earnings Call Summary for Q4/2025

  • ImmuCell reported 4.3% growth in full-year product sales for 2025, despite a 1.6% decline in Q4, with stock rising 8.83% to $7.15 in premarket trading.
  • Domestic sales increased 8.7% in Q4 while international sales plummeted 52.6%, prompting the company to focus on expanding its First Defense product line.
  • CEO Oliver Taboukos expressed 'high confidence in future sales and profit growth potential' with plans for a $3 million investment in manufacturing capabilities.
  • The company paused Re-Tain product development following an FDA Incomplete Letter but forecasts positive EPS of $0.03 for FY2026 with revenue reaching $42.92 million.
Last Updated: 09/01/2026, 15:32
Read Full Transcript

Compare ICCC to Peers and Sector

Metrics to compare
ICCC
Peers
Sector
Relationship
P/E Ratio
23.8x−2.3x−0.6x
PEG Ratio
0.16−0.140.00
Price/Book
1.9x2.4x2.6x
Price / LTM Sales
2.0x9.3x3.4x
Upside (Analyst Target)
-71.1%44.9%
Fair Value Upside
Unlock6.9%6.3%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
5.56M / --
EPS Revisions
Last 90 days

People Also Watch

16.68
ACNT
+1.49%
1.210
GVH
+2.54%
46.50
FLXS
+11.62%
260.07
PLPC
0.00%
1.7944
CISS
-7.98%

FAQ

What Is the ImmuCell (ICCC) Share Price Today?

The live ImmuCell share price today is 6.110

What Stock Exchange Does ImmuCell (ICCC) Trade On?

ImmuCell is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for ImmuCell?

The stock symbol (also called a 'ticker') for ImmuCell is "ICCC."

What Is the Current ImmuCell Market Cap?

As of today, ImmuCell market capitalisation is 55.27M.

What Is ImmuCell's (ICCC) Earnings Per Share (TTM)?

The ImmuCell EPS is currently 0.26 (Trailing Twelve Months).

When Is the Next ImmuCell Earnings Date?

ImmuCell's next earnings report will be released on 25 Feb 2026.

Is ICCC a Buy or Sell From a Technical Analyst Perspective?

Based on today's ImmuCell moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has ImmuCell Stock Split?

ImmuCell has split 1 times. (See the ICCC stock split history page for full effective split date and price information.)

How Many Employees Does ImmuCell Have?

ImmuCell has 81 employees.

What is the current trading status of ImmuCell (ICCC)?

As of 03 Feb 2026, ImmuCell (ICCC) is trading at a price of 6.110, with a previous close of 6.110. The stock has fluctuated within a day range of 6.110 to 6.110, while its 52-week range spans from 4.280 to 7.600.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.